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In Vitro Functional and Immunomodulatory Properties of the
Lactobacillus helveticus MIMLh5-Streptococcus salivarius ST3
Association That Are Relevant to the Development of a Pharyngeal
Probiotic Product
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Department of Food Science and Microbiology, Universita` degli Studi di Milano, Milan, Italya; Department of Biomolecular Sciences and Biotechnology, Universita` degli
Studi di Milano, Milan, Italyb; School of Medicine, University of Tampere, Tampere, Finlandc; Institute of Biomedical Technology, Biomeditech, University of Tampere,
Tampere, Finlandd; Fimlab Ltd., Tampere, Finland,e Pirkanmaa Hospital District, Tampere, Finlandf; and Institute of Environmental Engineering and Biotechnology,
Tampere University of Technology, Tampere, Finlandg
The use of proper bacterial strains as probiotics for the pharyngeal mucosa is a potential prophylactic strategy for upper respira-
tory tract infections. In this context, we characterized in vitro the functional and immunomodulatory properties of the strains
Lactobacillus helveticusMIMLh5 and Streptococcus salivarius ST3 that were selected during previous investigations as promis-
ing pharyngeal probiotics. In this study, we demonstrated in vitro that strains MIMLh5 and ST3, alone and in combination, can
efficiently adhere to pharyngeal epithelial cells, antagonize Streptococcus pyogenes, and modulate host innate immunity by in-
ducing potentially protective effects. In particular, we found that the strains MIMLh5 and ST3 activate U937 humanmacro-
phages by significantly inducing the expression of the proinflammatory cytokine tumor necrosis factor alpha (TNF-). Nonethe-
less, the induction of the anti-inflammatory interleukin-10 (IL-10) byMIMLh5 or ST3 was never lower than that of TNF-,
suggesting that these bacteria can potentially exert a regulatory rather than a proinflammatory effect. We also found that the
strains MIMLh5 and ST3 induce cyclooxygenase 2 (COX-2) expression and demonstrated that toll-like receptor 2 (TLR-2) partic-
ipates in the recognition of the strains MIMLh5 and ST3 by U937 cells. Finally, we observed that these microorganisms grow effi-
ciently when cocultured in milk, suggesting that the preparation of a milk-based fermented product containing bothMIMLh5
and ST3 can be a practical solution for the administration of these bacteria. In conclusion, we propose the combined use of L.
helveticusMIMLh5 and S. salivarius ST3 for the preparation of novel products that display probiotic properties for the pharyn-
geal mucosa.
The administration of living microbial cells to humans or ani-mals to promote or maintain health is commonly known as a
“probiotic approach.” Traditionally, probiotic products are ex-
plicitly proposed to be effective in the gastrointestinal tract (GIT).
However, several probiotics have been designed for the vaginal
mucosa (35), the urinary tract (5), the skin (20), and the oral
cavity (38). The use of probiotics for the oropharyngeal tract
(OPT) is particularly promising. OPT dysfunctions are often re-
lated to the presence of microbial pathogens (for instance, Strep-
tococcus mutans, group A streptococci, or Porphyromonas gingiva-
lis) or to microbial dysbiosis. Furthermore, compared with the
distal GIT, the OPT is a more accessible site for microorganisms of
exogenous origin. For these reasons, the OPT is a potential target
for new, specifically designed probiotic products.
An excellent example demonstrating the potential of the
probiotic approach for the OPT is represented by the research
activity of J. R. Tagg and coworkers, who isolated the Strepto-
coccus salivarius strain K12 (45). Strain K12 has a marked abil-
ity to inhibit pathogenic bacteria, mainly due to the production
of three different bacteriocins, salivaricins A2, B, and 9 (44).
Strain K12 was also demonstrated to be able to colonize the
upper respiratory tract (17) and to downregulate the innate
immune responses of human epithelial cells (8). The scientific
results from the Tagg lab studies supported the creation of a set
of probiotic pharmaceutical products (lozenges, powders, and
chewing gum), commercialized under the name of BLIS, that
were specifically designed for the prevention or treatment of
dysfunctions such as cavities, periodontitis, halitosis, and
pharyngitis. In July 2011, the oral probiotic products BLIS K12
were granted generally recognized as safe (GRAS) status by the
United States Food and Drug Administration (FDA), enabling
this probiotic to be included as an ingredient in food products
within the United States.
Recently, we published two studies in which a selection of pro-
biotic and dairy bacteria and new oral isolates were screened in
vitro for their ability to adhere to human pharyngeal cell layer and
keratinocytes, antagonize Streptococcus pyogenes, and modulate
host immune system responses (13, 14). As a result of these stud-
ies, we selected the oral isolate Streptococcus salivarius ST3 and the
dairy strain Lactobacillus helveticusMIMLh5 as new probiotic can-
didates for the pharyngeal mucosa. In this report, we show the
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results of further investigations of these bacteria. We analyzed in
vitro the potential probiotic properties of these bacteria when em-
ployed in combination. Specifically, we examined their ability to
adhere to FaDu human pharyngeal cells, to antagonize Streptococ-
cus pyogenes, and to modulate the immune response of macro-
phages. Particularly, since the immunological study of the in-
teraction between probiotic bacteria and the oropharyngeal
mucosa has been based exclusively on epithelial cells, in this
study we assessed the responses induced by bacteria in host
cells properly belonging to the immune system. To explore the
potential of combining strains ST3 and MIMLh5 in a fer-
mented food product, we also studied the growth of S. sali-
varius ST3 in the presence of different sugars and in milk in
coculture with strain MIMLh5. Our results support the possi-
bility of producing a novel milk-based fermented food product
to be used as probiotic for the oropharyngeal mucosa.
MATERIALS AND METHODS
Bacterial strains, culture conditions, and growth experiments. Lactoba-
cillus helveticus MIMLh5 was grown at 42°C in MRS broth (Difco Labo-
ratories Inc., Detroit, MI). Streptococcus salivarius ST3 was cultivated at
37°C in M17 broth (Difco Laboratories) supplemented with 2% glucose.
The growth curves of strain ST3 were determined with 384-well microtiter
plates using a BioTek Synergy HT multimode microplate reader (AHSI
S.p.A., Bernareggio, Italy) to measure growth in M17 broth supplemented
with 2%, 1%, 5‰, 2.5‰, 1.25‰, or 0.625‰ of one of the following
sugars: fructose, galactose, glucose, inulin, lactose, lactulose, sucrose, or
fructooligosaccharides (FOS). All sugars were purchased from Sigma-Al-
drich (Steinheim, Germany), with the exception of FOS, which were from
Actilight (Giulio Gross S.p.A., Trezzano sul Naviglio, Italy). The prepara-
tion of 384-well microtiter plates was conducted with an epMotion auto-
mated pipetting system (Eppendorf, Milan, Italy). Acidification curves
were determined by inoculating skim milk (Difco) (1% inoculum) with
an overnight culture of MIMLh5 and ST3 alone or in coculture and re-
cording the pH every hour for 24 h with a pH meter recorder (XS instru-
ments pH 2100; Opto-Lab, Concordia, Italy). Recombinant S. pyogenes
strain C11LucFF (emm type 77) was grown at 37°C in BHI medium (Difco)
supplemented with 0.3% yeast extract and 5g ml1 of chloramphenicol.
FaDu cell layer preparation. In vitro cultivation. FaDu cells (human
pharynx carcinoma cell line; ATCC HTB-43) were routinely grown in
Eagle’s minimum essential medium supplemented with 10% (vol/vol)
heat-inactivated (30 min at 56°C) fetal calf serum, 100 U ml1 penicillin,
100 mg ml1 streptomycin, 0.1 mM nonessential amino acids, and 2 mM
L-glutamine (EMEM) and were incubated at 37°C in a water-jacketed
incubator in an atmosphere of 95% air and 5% carbon dioxide.
Bacterial adhesionon the FaDu cell layer.FaDu cell monolayers were
grown in 3-cm petri plates on microscope cover glasses until they reached
confluence. Next, the cell layers were carefully washed twice with phos-
phate-buffered saline (PBS), pH 7.3. The bacterial cell concentrations of
overnight cultures were determined microscopically with a Neubauer Im-
proved counting chamber (Marienfeld GmbH, Lauda-Königshofen, Ger-
many). Bacterial cells were recovered by centrifugation and resuspended
in PBS to obtain a concentration of 108 cells per ml. Two milliliters of the
bacterial suspension were incubated with a FaDu cell monolayer for 1 h at
37°C. Afterward, the monolayers were washed 3 times with PBS, fixed for
8 min with 2 ml of methanol, and stained with 2 ml of Giemsa’s stain
(Carlo Erba Reagenti S.p.A., Rodano, Italy). The cover glasses were then
washed 5 times with 1 ml of PBS, dried, and examined microscopically
(100magnification, with oil immersion). The adherent bacteria from 20
randomly selected microscopic fields were counted, and average counts
were determined.
Bacterial antagonism assay on the FaDu cell layer. Antagonism
against Streptococcus pyogenes was studied using the bacterial exclusion
method on FaDu cell layers as previously described (13). In brief, 2 108
cells ml1 of a tester strain suspension in PBS were preincubated with the
FaDu cell layer for 1 h. The FaDu cells were then washed with PBS and
incubated with 2  108 cells ml1 of the indicator strain (S. pyogenes
bioluminescent recombinant strain C11LucFF) for 1 h. After the second
incubation, FaDu cell layers were quickly washed twice with 1 ml of PBS
(pH 7.3), and D-luciferin (Sigma-Aldrich) was added at a final concentra-
tion of 12.5M in citrate buffer, pH 5. Immediately, bioluminescence was
measured with a Victor 3 luminometer (PerkinElmer, Monza, Italy). Each
tester strain was analyzed in triplicate in at least two independent experi-
ments. Unpaired Student’s t test was used to detect statistically significant
differences.
Study ofNF-B activation in FaDu cells. Stably transfected FaDu cell
lines were generated by transfecting cells with the plasmid pNiFty2-Luc
(Invivogen, Labogen, Rho, Italy) as described by Guglielmetti et al. (13).
This plasmid contains a promoter combining five nuclear factor-B (NF-
B)-binding sites and the luc firefly luciferase reporter gene. Stimuli that
activate NF-B promote its binding to the vector promoter, resulting in
the expression of the luciferase gene. After growth in the presence of 50g
ml1 zeocin, the FaDu cells were detached by trypsinization and then
resuspended in EMEM at a concentration of 250,000 cells ml1 in the
presence of 100 mM HEPES (pH 7.4). Subsequently, 50 l of a tester
bacterial suspension containing 2.5  109 or 2.5  108 cells ml1 was
added to 450 l of the FaDu cell suspension, resulting in a multiplicity of
infections (MOI) of approximately 1,000 or 100, respectively. After incu-
bation at 37°C for 4 h, the samples were kept in ice and sonicated at
maximum power for 5 s using a Bandelin Sonoplus ultrasonic homoge-
nizer (Bandelin Electronic GmbH & Co., Berlin, Germany). Insoluble
particles were removed by centrifugation, and 100 l of the supernatants
were dispensed in duplicate into the wells of a 96-well white microtiter
plate (PerkinElmer, Monza, Italy) using an epMotion automated pipetting
system (Eppendorf). Next, 12.5 l of a 10 mM ATP solution (1 mM final
concentration) and 12.5l of 0.1 mM D-luciferin were added to the wells,
and bioluminescence was immediately measured with a Victor3 1420
multilabel counter (PerkinElmer). The maximum of the light production
curve was considered for comparison of results. All conditions were ana-
lyzed in triplicate in at least two independent experiments. Unpaired Stu-
dent’s t test was used to detect statistically significant differences.
Cell culture, growthconditions, and stimulationof theU937human
macrophage cell line. The cell line U937 (ATCC CRL-1593.2) was de-
rived from a human histiocytic lymphoma (37). These cells are main-
tained as replicative, nonadherent cells and have many of the biochemical
and morphological characteristics of blood monocytes (15). When treated
with phorbol myristate acetate (PMA), U937 cells differentiate to become
adherent, nonreplicative cells with characteristics similar to those of tissue
macrophages, including similar isoenzyme patterns (33) and other phe-
notypic markers (15). The normal growth medium for the U937 cells
consisted of RPMI 1640 medium (Lonza, Basel, Swiss) supplemented with
10% (vol/vol) fetal bovine serum (FBS) (Gibco-BRL, Life Technologies,
Milan, Italy), 2 mM L-glutamine, 100 units ml1 penicillin, and 100 g
ml1 streptomycin (Sigma-Aldrich). U937 cells were seeded at a density
of 5 105 cells well1 in 12-well plates and incubated at 37°C in a humid-
ified atmosphere of 95% air and 5% CO2. Differentiation was induced by
the addition of PMA (Sigma-Aldrich) into the cellular medium at a final
concentration of 100 nM and was allowed to proceed for 48 h. Afterward,
cells were washed once with sterile PBS buffer to remove all nonadherent
cells. One hour before the bacteria were added to the cells, the culture
media was replaced with RPMI 1640 medium supplemented with 1%
(vol/vol) FBS to allow the cells to adapt. Bacteria were used at MOIs of 100
and 1,000, and lipopolysaccharide (LPS; final concentration of 1g ml1)
from Escherichia coli 0127:B8 (Sigma-Aldrich) was used as the positive
control for proinflammatory stimulus in U937 cells. An untreated sample,
i.e., only RPMI 1640 medium with 1% (vol/vol) FBS, was used as the
control.
Inhibition assay with Toll-like receptor neutralizing antibodies.
Human anti-Toll-like receptor 2 (anti-TLR-2) antibody (Invivogen) was
Taverniti et al.
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added to U937 cells 1 h before the stimulation with bacterial cells. A
human immunoglobulin A2 (IgA2) isotype control (Invivogen) was used
as the control to exclude nonspecific binding and blocking activity of the
antibody. Both the anti-TLR2 and IgA2 isotype control were used at 5 g
ml1. This concentration was determined by examining the neutralizing
efficacy of anti-TLR2 with zymosan from Saccharomyces cerevisiae (Invi-
vogen) as the ligand.
Preparation of RNA and reverse transcription. After incubating
U937 cells at 37°C for 4 h, the supernatant was carefully removed from
each well and the total cellular RNA was isolated from the adhered U937
cells with an RNeasy Minikit (Qiagen, Inc., Valencia, CA). Afterward,
RNA concentration and purity were determined with a NanoDrop spec-
trophotometer (ND-1000, Thermo Fischer Scientific), and reverse tran-
scription to cDNA was performed with an iScript Select cDNA synthesis
kit (Bio-Rad Laboratories, Hercules, CA) using the following thermal
cycle: 5 min at 25°C, 30 min at 42°C, and 5 min at 85°C.
Real-time quantitative PCR. The mRNA expression levels of cyto-
kines were analyzed with SYBR green technology in real-time quanti-
tative PCR (qPCR) using SsoFast EvaGreen Supermix (Bio-Rad) on a
Bio-Rad CFX96 system according to the manufacturer’s instructions.
The primers used are as follow (5=¡3=): 18srRNA forward, ATCCCT
GAAAAGTTCCAGCA; 18srRNA reverse, CCCTCTTGGTGAGGTCA
ATG; interleukin-10 (IL-10) forward, AGCAGAGTGAAGACTTTCT
TTC; IL-10 reverse, CATCTCAGACAAGGCTTGG; tumor necrosis
factor alpha (TNF-) forward, TCAGCTCCACGCCATT; TNF- reverse,
CCCAGGCAGTCAGATCAT; cyclooxygenase 2 (COX-2) forward, CCC
TTGGGTGTCAAAGGTAA; COX-2 reverse, TGAAAAGGCGCAGTTT
ACG. All primers were selected using Primer3Plus software (http://www
.bioinformatics.nl/cgi-bin/primer3plus/primer3plus.cgi), and the specificity
of the primers was tested with melting curves during amplification and by 1%
agarose gels. Quantitative PCR was carried out according to the following
cycle: initial hold at 96°C for 30 s and then 40 cycles at 96°C for 2 s and 60°C for
5 s. Gene expression was normalized to that of the 18S ribosomal DNA
(rDNA) gene. The amount of template cDNA used for each sample was 12.5
ng. All results regarding cytokine mRNA expression levels are reported as the
fold of induction (FOI) respective to the control (namely, unstimulated
U937), to which we attributed an FOI of 1.
RESULTS AND DISCUSSION
In previous studies, we selected Streptococcus salivarius ST3 and
Lactobacillus helveticus MIMLh5 from several oral bacterial iso-
lates and probiotic/dairy bacteria as potential probiotics for the
pharyngeal mucosa (13, 14). In this study, we evaluated the pos-
sibility of using strains ST3 and MIMLh5 in combination by as-
sessing their in vitro probiotic and immunologic properties.
ST3/MIMLh5 cosuspension did not affect adhesion and an-
tagonistic properties of the individual strains on the FaDu cell
layer. In previous studies, strains ST3 and MIMLh5 showed sim-
ilar efficient adhesive and antagonistic features, but they displayed
different behaviors both in the activation of NF-B and in the
profile of induced cytokines (13, 14). Therefore, we evaluated in
vitro the potential probiotic properties of strains ST3 and
MIMLh5 used in combination. We first studied the interaction
with FaDu human pharyngeal cell line in terms of adhesion and
ability to antagonize Streptococcus pyogenes (Fig. 1). The adhesion
of each strain was not affected when the other was also present,
indicating that there is no competition for adhesion sites between
MIMLh5 and ST3 in our test conditions (MOI of 1000 for each
bacterium) (Fig. 1A). The adhesion index (the number of bacteria
adhered per 100 FaDu cells) for the two strains, in fact, was not
significantly different when a strain was alone or in coculture (P
value of 0.835 or 0.507, respectively); both conditions resulted in
an adhesion index of approximately 2,000 (data not shown).
In the following series of experiments, we measured the biolu-
minescence produced by S. pyogenes C11LucFF as an indication of
the exclusion antagonism exerted by strains ST3, MIMLh5 and
their mixed suspension. L. helveticus MIMLh5 showed better an-
tagonism against S. pyogenes (72% reduction of luminescence),
but S. salivarius strain ST3 could also effectively antagonize the
pathogen (53% luminescence reduction). When the tester bacte-
ria were used in combination (MOI of 1,000 each), the antagonis-
tic activity was maintained at the highest level (72% reduction),
indicating that the two strains can coexist without reducing their
in vitro exclusion ability (Fig. 1B).
The effect of strain MIMLh5 on NF-B activation in FaDu
epithelial cells is predominant over that of strain ST3. An in-
creasing number of in vitro and in vivo experiments support the
idea that probiotic bacteria confer their health benefits to the host
by interacting with the immune system (7, 23). The ability to
modulate host immune responses in vitro has also been shown for
bacteria that have been proposed as probiotics for the OPT, such
as Streptococcus salivarius K12 (8) and the two strains included in
this study (13, 14). Particularly, in vitro immunological tests with
FaDu cells revealed different responses to S. salivarius ST3 and L.
helveticus MIMLh5 (13, 14). While strain MIMLh5 reduced IL-8
and IL-6 secretion (14), ST3 had only a limited effect on these
cytokines but drastically inhibited IL-1 and stimulated macro-
phage inflammatory protein 1 (MIP-1) (13). It has been pro-
posed that the reduction in IL-8 and IL-6 secretion resulting from
exposure to strain MIMLh5 can be attributed to the inhibition of
NF-B activation (14). In contrast, S. salivarius ST3 promoted the
activation of NF-B (13). In this study, we explored the effect of
strains ST3 and MIMLh5 in combination on NF-B activation in
FaDu cells. As observed in previous investigations (13, 14), L.
helveticus MIMLh5 decreased the NF-B-dependent production
of bioluminescence, while ST3 showed a stimulatory effect (Fig.
1C). When the two bacterial strains were used in combination at
the same multiplicity of infection (MOI of 1,000 each), activation
of NF-B was reduced to an extent similar to that determined by
MIMLh5 alone (Fig. 1C), indicating that the inhibitory effect of
this bacterium on NF-B-mediated responses is predominant
over the outcome induced by strain ST3.
Effect of the strains MIMLh5 and ST3 on activation of U937
humanmacrophages. Studies on the immunomodulatory effects
of probiotics for the oropharyngeal mucosa have thus far concen-
trated mainly on immune responses at the epithelial cell level (8,
13). An evaluation of the responses by cells involved in the im-
mune system is thus required. In this study, we quantified via
reverse transcription (RT)-qPCR the gene expression of TNF- (a
cytokine involved in inflammatory responses [4]) and IL-10 (a
potent anti-inflammatory interleukin that inhibits the production
of proinflammatory cytokines in several cell types [9, 11]) in
PMA-differentiated U937 human macrophages. We tested the
strains MIMLh5 and ST3 alone and in combination (coincuba-
tion) at MOIs of 100 and 1,000. In all tested conditions, strains
MIMLh5 and ST3 induced a higher IL-10/TNF- ratio than lipo-
polysaccharide (LPS) from Escherichia coli, a potent proinflam-
matory stimulus. Unlike LPS, the induction of IL-10 by MIMLh5
or ST3 alone was never lower than that of TNF- (Fig. 2A). Strain
ST3, in particular, triggered profound IL-10 expression. In coin-
cubation experiments, we used a total MOI (i.e., the sum of the
bacterial cell numbers of both strains) corresponding to the MOI
of the bacterial strains employed individually to see possible syn-
Potential Probiotic Properties of MIMLh5/ST3
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ergistic effects. At the lower MOI tested, the mixed suspension of
MIMLh5 and ST3 resulted in an intermediate cytokine induction
compared to that of the single strains (Fig. 2A). In contrast, syn-
ergism was observed at the MOI of 1,000; the combination of
MIMLh5 and ST3 caused a significant increase in the expression of
both TNF- and IL-10 (Fig. 2A). These data show that the bacte-
rial cell concentration affects the immune response of U937 cells;
a dose-dependent approach should be therefore considered when
defining a specific immunological effect of a bacterial strain, as
demonstrated in previous works (10).
In this study, the strains MIMLh5 and ST3 significantly in-
duced the expression of the proinflammatory cytokine TNF-.
Previous studies have shown that different Lactobacillus species
can trigger pronounced proinflammatory activity in DCs (6, 43)
and in macrophages (26). Macrophages are professional phago-
cytes that reside in the secondary lymphoid organs as well as in
almost all tissues, including the tonsils (47), serving as sentinels to
detect microbial invaders (1). Upon the recognition of pathogen-
associated molecular patterns (PAMPs [18]), macrophages pro-
duce inflammatory mediators, such as cytokines and chemokines,
that alert the immune system to the infection of injury. A proin-
flammatory behavior that results in the activation of cell-mediated
(Th1-type) immunity, like that observed for MIMLh5 and ST3,
could thus be crucial in combating intracellular pathogen attacks
and viral infections and alerting the host’s immune system. Other
studies have reported that most lactic acid bacterial strains that
have been tested could induce a Th1 response, even though this
capability is strictly dependent on the specific strain and dose used
(29, 31). Notably, in the same studies, some strains of S. thermo-
philus, a species phylogenetically close to S. salivarius, induced a
high level of IL-10 (29). In our experiments, S. salivarius ST3 in-
duced a higher level of IL-10 than TNF-. Furthermore, the in-
creased production of the anti-inflammatory cytokine was more
pronounced in ST3 than in MIMLh5 at the highest MOI tested
(Fig. 2A). Therefore, we speculate that the presence of both bac-
teria, even at high doses (MOI of 1,000), might not result in det-
rimental effects. The regulatory effect of the significant IL-10 ex-
pression could protect against secondary outcomes that can occur
after streptococcal infections, namely, reactive inflammatory con-
ditions such as rheumatic disease (32).
The strains MIMLh5 and ST3 induce cyclooxygenase 2
(COX-2) expression in U937 cells and in BMDCs. Cyclooxygen-
FIG 1 Probiotic properties of Lactobacillus helveticus MIMLh5 and Streptococcus salivarius ST3 on a FaDu human pharyngeal cell layer. (A) Bacterial adhesion
as observed with Giemsa staining under a light microscope; FaDu cell nuclei appear in red. (B) Antagonistic exclusion activity against bioluminescent Strepto-
coccus pyogenes C11lucFF; the control is a cell layer treated only with PBS before incubation with S. pyogenes. (C) Effect of bacteria on FaDu cells stably transfected
with an NF-B/luciferase reporter vector. The control is a FaDu cell layer incubated without bacterial cells. MOI, multiplicity of infection (bacterial cells per FaDu
cell). IL-1 was used as the positive control for NF-B activation. Data in histograms are the means ( standard deviations) from at least three independent
experiments conducted in triplicate. Bacterial and FaDu cell luciferase activities are expressed as relative luminescence units (RLU). Asterisks indicate statistically
significant differences compared to the control (P 0.001).
Taverniti et al.
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ase (COX), or prostaglandin synthase H (PGH), is a homodimer
enzyme involved in the synthesis of prostaglandins (PGs) from
arachidonic acid (12). PGs are involved in several physiological
processes and contribute to the protection of the gastrointestinal
mucosa (46, 27). Two isoforms of the COX enzyme have been
identified and described (21). COX-1 is constitutively expressed
in a wide range of tissues, whereas COX-2 is constitutively ex-
pressed in very few tissues but is induced by several stimuli, in-
cluding bacterial components (16). We investigated the effect of
the strains MIMLh5 and ST3 on COX-2 gene activation in the
U937 cell model. L. helveticus MIMLh5 and S. salivarius ST3 in-
duced COX-2 gene expression to similar levels. The expression
levels for MIMLh5 and ST3 were 5.20 and 5.75, respectively, at an
MOI of 100, and 13.08 and 14.12, respectively, at an MOI of 1,000
(Fig. 2B). The association of the two bacteria resulted in an en-
hanced transcription of the gene (Fig. 2B). In similar experiments,
we also observed a strong increase in COX-2 gene expression in
murine bone marrow-derived dendritic cells (BMDCs) (see Fig.
S1 in the supplemental material).
Although other studies have suggested that lactic acid bacteria
could affect COX-2 secretion, there is no clear consensus in the
literature. For instance, several probiotic preparations were found
to reduce the amount of prostaglandins and levels of COX-2 gene
expression at the intestinal level in murine models (3, 41) and in
vitro (24). In contrast, other papers reported a significant upregu-
lation ofCOX-2 expression levels by probiotic bacteria in vitro (19,
30) and in vivo (19, 22). Lactobacillus acidophilus, a species phylo-
genetically related to L. helveticus, was reported to significantly
increase COX-2 expression and PGE2 secretion in the human co-
lon cancer cell line Colo320 (30). Differences in tested strains and
model systems likely explain the lack of consensus found in the
literature.
The ability of the strains MIMLh5 and ST3 to induce COX-2
expression suggests that these bacteria could directly affect in-
flammatory processes not only by modulating cytokine secretion
but also by inducing prostaglandin production. COX-2 is in-
volved in the induction of oral tolerance through the action of PGs
in guiding T cells toward an immunosuppressive phenotype (28)
and in resolving inflammation (42). The observed effect of
MIMLh5 and ST3 on the activity of the COX-2 gene could thus be
of immediate benefit for the host’s mucosa; furthermore, rapid
COX-2 upregulation in response to injury or inflammation has
been reported to restore mucosal integrity (40).
TLR-2 participates in the recognition of the strainsMIMLh5
and ST3 by U937 cells. To gain information on possible signaling
pathways involved in the immune responses induced by L. helve-
ticus MIMLh5 and S. salivarius ST3, we investigated which Toll-
like receptor (TLR) recognizes these bacteria. TLRs are a class of
transmembrane proteins involved in innate immunity (2); in
mammals, they work as pattern recognition receptors (PRRs) and
participate in detecting various conserved microbial molecules,
such as lipopolysaccharide (LPS), lipoteichoic acid (LTA), pepti-
FIG 2 Transcription analysis of cytokine genes in U937 cells stimulated with Lactobacillus helveticus MIMLh5 and Streptococcus salivarius ST3 after 4 h of
incubation with bacterial strains used alone or in association at two different MOIs. Lipopolysaccharide (LPS) was used as the positive control at a concentration
of 1 g ml1. The values are the means ( standard deviations) for a result representative of three independent experiments, expressed as the fold change in
induction relative to the result for the control (U937 unstimulated cells), which was set at a value of 1. Asterisks indicate statistically significant differences
compared to results for the corresponding control (*, P 0.05). (A) Expression levels of IL-10 and TNF-. (B) Expression levels ofCOX-2. (C) Expression levels
of IL-10 and TNF- in the presence of a neutralizing antibody against TLR-2 (anti-TLR2). Anti-TLR2 was added to U937 cells 1 h before stimulation with
bacteria. Immunoglobulin-A2 isotype (IgA2) was used as the control for nonspecific blocking activity.
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doglycan (PGN), bacterial lipoproteins, lipoarabinomannan, and
zymosan (25). More specifically, TLR-2 forms heterodimers with
TLR-1 or TLR-6 and primarily interacts with Gram-positive bac-
teria by recognizing PGN, LTA, and lipoproteins (39).
In this study, as preliminary information needed to set up the
experiment, we observed that 5 g ml1 of zymosan induced in
U937 cells a 5-fold reduction in the expression level of TNF-, a
cytokine known to be induced in the downstream pathway acti-
vated by TLR-2. We then performed experiments with a neutral-
izing antibody against TLR-2 (anti-TLR2-Ab) to partially block its
ability to bind ligands. An IgA isotype control was also used to
exclude nonspecific binding to U937 cell receptors. After a 1-h
preincubation with an anti-TLR2 neutralizing Ab (5g ml1), we
stimulated the U937 cells for 4 h with bacteria. We then evaluated
the expression of the genes that encode TNF- and IL-10 by using
RT-qPCR. When TLR-2 was blocked with anti-TLR2, we ob-
served significantly less TNF- mRNA, both when strains
MIMLh5 and ST3 were used individually and when they were used
in combination (Fig. 2C). These results indicate that TLR-2 is
involved in mediating the immunostimulatory activity of both
strains. These data are consistent with previous studies that
showed that the immunomodulatory activity elicited by lactoba-
cilli involves TLR-2 in macrophages (36) and in dendritic cells (43,
49). However, preincubation with anti-TLR2 resulted in a reduc-
tion of IL-10 expression only with strain ST3, whereas MIMLh5-
mediated expression of IL-10 was not affected (Fig. 2C), indicat-
ing that receptors independent from TLR-2 may be involved in the
induction of this cytokine. The interference of the anti-TLR2-Ab
with IL-10 induction that we observed in our study with strain ST3
is in agreement with the literature. Molecules able to induce IL-10
in a TLR2-dependent manner have been already described (34,
48). It is plausible that a similar response mechanism is triggered
by S. salivarius ST3 in U937 cells.
When the strains were combined, the reduction of the proin-
flammatory cytokine TNF- was similar to that of ST3 alone
(1.43- and 1.34-fold reduction, respectively). Even though anti-
TLR2 generally reduced TNF- induction, the relative increase of
TNF- gene expression caused by the bacteria in combination
compared to bacteria employed individually was markedly higher
when TLR-2 was blocked with anti-TLR2 than that in control
conditions (i.e., in the presence of IgA2) (Fig. 2C). In other words,
the synergistic effect of using both strains was intensified by the
presence of the anti-TLR2 antibody. As a consequence, when
TLR-2 was blocked, the IL-10/TNF- ratio increased only slightly
(approximately 18%) with bacteria in combination, whereas the
ratio was nearly doubled with the use of the individual strains. We
can therefore speculate that PRRs other than TLR-2 are involved
in the recognition of these bacteria. It might also be hypothesized
that blocking TLR-2 can impact the formation of heterodimers
with other TLRs and/or the cooperation of TLR-2 with other types
of receptors (such as scavenger receptors), therefore causing dif-
ferent cytokine responses.
Strains ST3 andMIMLh5 can be used in combination to fer-
ment bovine milk. In light of the in vitro functional properties of
L. helveticus MIMLh5 and S. salivarius ST3 in combination, we
examined the possibility of cocultivating these bacteria in bovine
milk and potentially employing MIMLh5 and ST3 in dairy prod-
ucts. L. helveticus MIMLh5 is a natural whey starter culture that is
well adapted to grow in bovine milk. In contrast, S. salivarius is a
human oral commensal isolate that cannot proliferate when cul-
tivated in milk due to its limited ability to use lactose as the sole
carbon and energy source. We determined the growth curve of
ST3 with eight different carbohydrates at six concentrations in
M17 medium (see Fig. S2 in the supplemental material). Strain
ST3 displayed optimal growth in the presence of glucose, sucrose,
fructose and fructooligosaccharides (FOS); its growth was signif-
icantly reduced with inulin and lactose but was not detectable with
galactose and lactitol (Fig. 3A). Interestingly, strain ST3 metabo-
lized Actilight (Fig. 3B), a commercial product consisting of a
mixture of short-chain FOS (1-kestose, nystose, and fructosylnys-
tose) that is frequently used as a prebiotic supplement. When we
added one of the four sugars that are efficiently metabolized by
ST3 to skim milk, ST3 growth became similar to that in M17
supplemented with the same sugar. Subsequently, we performed
acidification curves by monitoring the pH in skim milk supple-
mented with 2% glucose after a 1% inoculum of the overnight
cultures of strains ST3 and MIMLh5 alone and in coculture. The
association of the two strains resulted in a faster acidification of
FIG 3 Growth curves of Streptococcus salivarius ST3. (A) Growth in M17
medium supplemented with 2% of 8 different carbon sources. (B) Growth in
M17 medium supplemented with 6 different concentrations of Actilight fruc-
tooligosaccharides (FOS). The curves are representatives of two experiments
carried out in sextuplicate.
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the medium (Fig. 4). In fact, after 6 h of incubation at 42°C, ST3
and MIMLh5 monocultures reached pH 5.2 and 5.5, respectively,
whereas their coculture reduced the pH to 4.9 in skim milk sup-
plemented with 2% glucose or FOS (Fig. 4). After 6 h of coincu-
bation in skim milk supplemented with glucose at 42°C, ST3 and
MIMLh5 reached a number of viable cells of 9.5 108 and 8.9
107 CFU ml1, respectively (Fig. 4), indicating that both strains
contributed to the milk acidification. These data support the po-
tential of using a combination of strains ST3 and MIMLh5 to
ferment milk for the production of a novel food product.
Conclusion. There is an increasing interest in prophylactic
strategies effective for upper respiratory tract infections, which
represent a major cause of medical prescription for antibiotics,
especially in children. The identification of bacterial strains that
could be used as probiotics for the pharyngeal mucosa is one po-
tential strategy.
This study is part of an ongoing research project designed to
identify new potential probiotic bacteria for the pharyngeal mu-
cosa and to develop novel food products for an effective adminis-
tration of these probiotics. We presented a further characteriza-
tion of the strains MIMLh5 and ST3 that were selected during
previous investigations as the most promising pharyngeal probi-
otics (13, 14). We demonstrated in vitro that strains MIMLh5 and
ST3, alone and in combination, can efficiently adhere to pharyn-
geal epithelial cells, antagonize S. pyogenes, and modulate host
innate immunity by inducing potentially protective effects. We
gave particular attention to bacterial immunomodulatory prop-
erties because modulation of the host’s immunity is one of the
most commonly purported benefits of the consumption of probi-
otics and is supported by an increasing number of in vitro and in
vivo studies (7). We found that the combination of MIMLh5 and
ST3 resulted in a synergistic effect, according to cytokine induc-
tion, that might help the host immune system react to potential
pathogens while maintaining a balance between pro- and anti-
inflammatory cytokines, thus preventing possible exaggerated re-
sponses. Finally, we observed that these microorganisms grow ef-
ficiently when cocultured in milk, suggesting that the preparation
of a milk-based fermented product containing both MIMLh5 and
ST3 can be a practicable solution for the administration of these
bacteria.
In conclusion, we propose the combined use of Lactobacillus
helveticus MIMLh5 and Streptococcus salivarius ST3 for the prep-
aration of novel products that display probiotic properties for the
pharyngeal mucosa. A clinical study will soon be carried out to
confirm that the in vitro properties exerted by strains MIMLh5
and ST3 can result in an actual benefit to the human host in terms
of preventing oropharyngeal infections.
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